Heterocyclic Compounds for IAP Binding and Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds used for targeted protein degradation, particularly those binding to E3 ligases like IAPs, face challenges in drug efficacy onset, pharmacokinetics, solubility, drug interactions, safety, and stability.
Innovation Solution
Development of novel heterocyclic compounds represented by specific formulas that exhibit excellent IAP binding activity or bind to other target proteins, enhancing therapeutic effects as targeted protein degraders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current compounds are used for targeted protein degradation, then protein degradation function is achieved, but drug efficacy onset, pharmacokinetics, solubility, safety, and stability are insufficient
Solution Approach 1:
The patent modifies the chemical structure of IAP inhibitor compounds by introducing specific heterocyclic groups and substituent patterns (formula I with various R groups and A fragments), which changes the physicochemical parameters to improve both solubility and therapeutic efficacy simultaneously
2Reliability
If current compounds are used for targeted protein degradation, then protein degradation function is achieved, but drug interactions and safety profile are insufficient
Solution Approach 1:
The patent introduces specific functional groups and substituent patterns at particular positions in the molecular structure (B substituent definitions including pyrazolyl, indolyl, indazolyl groups with specific substituents), creating localized chemical features that improve safety profile while maintaining target specificity and reducing unwanted drug interactions
3Reliability
If current compounds are used for targeted protein degradation, then IAP binding activity is achieved, but inhibitory activity and stability are insufficient
Solution Approach 1:
The patent creates composite molecular structures combining IAP inhibitor pharmacophores (A fragments) with specific heterocyclic moieties (B substituents including nitrogen-containing aromatic rings), forming composite compounds that simultaneously enhance inhibitory activity against IAP-caspase complex and improve metabolic stability for prolonged duration of action
Data Source
AI summary
One of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity. Another of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity and exhibits a protein degradation induction activity. The present invention provides a compound represented by formula (I) (the symbols in the formula are as defined in the present Description) and salts thereof.